Sucraid® (sacrosidase) Oral Solution

Please join us for a virtual presentation

Understanding, Diagnosing, and Treating Congenital Sucrase-Isomaltase Deficiency

Webcast Login Information to be provided prior to the program

KEYNOTE SPEAKER

Anne Boney, MEd, RD, LDN

Wednesday, August 12, 2020

8:30 PM ET (7:30 PM CT, 6:30 PM MT, 5:30 PM PT)

Tuesday, August 18, 2020

7:00 PM ET (6:00 PM CT, 5:00 PM MT, 4:00 PM PT)

Wednesday, September 16, 2020

6:00 PM ET (5:00 PM CT, 4:00 PM MT, 3:00 PM PT)

Thursday, September 24, 2020

6:00 PM ET (5:00 PM CT, 4:00 PM MT, 3:00 PM PT)

REGISTRATION

Advanced registration is required. To register, visit:

http://www.pharmethodportal.com/qolmedical/register

Please enter the Program ID:

8/12 - Program ID 10458

8/18 - Program ID 10459

9/16 - Program ID 10462

9/24 - Program ID 10461

Or contact your local QOL Medical representative

Indication

Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

- Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
- Do not use Sucraid® with patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
- Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
- Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
- Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
- The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
- DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
- Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light.
- For full Prescribing Information, please visit: https://www.sucraid.com/wp-content/uploads/2019/12/SucPI_R0219.pdf

QOL Medical

According to the PhRMA Code on Interactions with Healthcare Professionals, attendance at this informational presentation is limited to healthcare professionals. Accordingly, attendance by guests or spouses cannot be accommodated.